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Objective: The nature and magnitude of the immunologic response to 
implantation of human cryopreserved aortic valve allografts was investi- 
gated. Methods: Twenty aortic valve allograft recipients were investigated 
for donor-specific antibody and T-cell-mediated responses with serial flow 
cytometric and microlymphocytotoxic crossmatch assays and one-way 
mixed lymphocyte cultures. Results: Donor-specific immunoglobulin G 
antibodies to class I and II human leukocyte antigens were first detected in 
the serum of all aortic valve allograft recipients at 30 days after implan- 
tation and persisted in substantial amounts in all but one of the recipients 
at day 365. Recipient T-cell alloreactivity toward donor lymphocytes was 
significantly increased at day 30 compared with levels before and 10 days 
after operation. Conclusions: Cryopreserved aortic valve allografts elicit a 
substantial allogeneic response in recipients. This alloreactivity may con- 
tribute to the observed morphologic hanges in aortic valve allografts and 
eventual long-term deterioration of allograft function. (J Thorac Cardio- 
vasc Surg 1996;112:1260-7) 
~ ortic valve allografts (AVAs) sterilized by low- 
[dose antibiotics followed by early cryopreserva- 
tion (i.e., viable cryopreserved AVAs) combine the 
best long-term performance with the lowest compli- 
cation rate compared with alternative aortic valve 
replacements.i, 2 Comparison of human AVAs pre- 
pared by various methods indicates that the durabil- 
ity of cryopreserved A VAs may be explained by 
adequate tissue matrix preservation and possibly by 
survival of fibroblasts, which maintain the integrity 
of the AVAs for some time. 2' 3 Hemodynamic fail- 
ure of an AVA as a result of degeneration of the 
valve matrix may be caused by immunologic destruc- 
tion of fibroblasts or by prolonged mechanical stress 
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after leaflet distortion at implantation. 4' s Attempts 
to understand and possibly modify the process of 
degeneration are particularly relevant to treating 
younger ecipients, in whom degeneration is known 
to occur earlier. 4
The significance of an antiallograft immune re- 
sponse cannot be determined until the frequency, 
evolution, and magnitude of the main components 
of the reaction are defined. Previous studies from 
our group with the use of a heterotopic AVA rat 
model documented the evolution of both a donor- 
specific antibody and a T-cell-mediated immune 
response to fresh AVA tissue. 6The strategies of that 
study were repeated in the current study, which 
reports the findings of prospective assays of anti- 
body and T-cell responses to donor antigens in a 
group of 20 patients receiving cryopreserved AVAs 
during cardiac operations. 
Patients and methods 
Recipients and donors. Twenty recipients of AVAs 
comprising 17 men and 3 women (median age 47 years; 
range 20 to 69 years) were studied. Individual AVA 
recipients were designated by numbers 1 through 20, 
indicating their order of entry into the study. Replace- 
ments with AVA were carried out for degenerative aortic 
valve disease in 17 patients (including one replacement for 
a previous AVA). Pulmonary valve allografts were used to 
replace pulmonary valves in two patients with congenital 
right heart disease and in one patient whose own pulmo- 
nary valve was used as an autograft replacement of the 
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diseased aortic valve. An all-male control group (median 
age 64 years; range 49 to 71 years), included to ascertain 
the effect of operation and anesthesia, comprised five 
recipients of mechanical aortic valves (MV) and one 
recipient of a xenograft aortic valve (XV) (0.2% glutaral- 
dehyde-fixed porcine graft, Medtronic Intact, Minneapo- 
lis, Minn.) implanted for degenerative aortic valve disease. 
Fifteen patients had complete aortic root replacements, 
two had subcoronary aortic valve replacements (one with 
pulmonary autograft), one had an aortic valve replace- 
ment with the intraluminal cylinder technique, and two 
had pulmonary valve replacements alone. Concomitant 
surgical procedures included coronary artery bypass in 
two recipients and two control patients and a mitral valve 
replacement in one control patient. 
Two recipients of AVA were taking antiinflammatory 
doses (<0.5 mg/kg/day) of prednisone for treatment of 
chronic asthma. Transfusions of Red blood cells were 
given peri0peratively to four AVA recipients (to a maxi- 
mum of 4 units), one MV and one XV recipient (1 and 12 
units). Except for the patient who received an AVA 6 
years previously, no recipient had prior exposure to 
allogeneic human tissue. 
Serum or heparin-treated venous blood were obtained 
from recipients of AVAs immediately before operation 
(day 0) and approximately on days 10, 30, 90, and 365 after 
implantation. Control sera were taken at identical tilnes 
from the MV and XV recipients. 
Research protocols were approved by The Prince 
Charles and Princes Alexandra Hospitals' Medical Ethics 
Advisory Committees. All valve recipients tudied gave 
informed consent before participation. 
Allograft preparation. AVAs were obtained from mul- 
tiorgan donors and the native hearts of heart transplant 
recipients. The valves were processed as soon as POssible 
after crossclamp application and stored by the Queens- 
land Heart Valve Bank at The Prince Charles Hospital 
with the use of techniques developed by O'Brien and 
colleagues. 7 Valves obtained from multiorgan donors 
were incubated for 6 hours at 37 ° C in Nutrient Medium 
199 (M199, CSL, Parkville, Australia) containing the 
antibiotics penicillin (CSL, 30 /xg/ml) and streptomycin 
(CSL, 50/xg/ml) (M199 +AB). Valves obtained from heart 
transplant recipients received a brief wash in M199+AB 
only. The valves were then placed in 100 ml of M199 
containing 10% dimethylsulfoxide (DMSO) (Merck, 
Darmstadt, Germany) and heat sealed inside two Fenwal 
Cryocyte Freezing containers (Baxter Healthcare Co., 
Deerfield, Ill.). 
The packaged valves were then cryopreserved in a 
controlled-rate freezer (Model 1010A, Cryomed, Mt. Cle- 
mens, Mich.) at a rate of -1  ° C/minute down to -40 ° C 
and then transferred to the vapor phase of a liquid 
nitrogen freezer (Model 17K, Taylor-Wharton, Indianap- 
olis, Ind.) at temperatures below -135 ° C. The valves 
were stored for a minimum of 3 weeks before use. Only 
valves that demonstrated no microbial contamination i
tissue and fluid samples at the time of cryopreservation 
were released. When required for implantation, the se- 
lected valve was removed from the outer package and 
thawed in a 37 ° C saline bath, followed by four sequential 
2-minute washouts of the DMSO (i.e., 5% DMSO in 
M199, 2.5% DMSO in M199, M199 only, and M199 only). 
Donor mononuclear cells (MC) were isolated from 
multiorgan donor spleen or lymph nodes and from hepa- 
rin-treated venous blood of heart transplant recipients 
immediately before transplantation. 
Isolation of mononuclear cells. Peripheral blood 
mononuclear cells (PBMC) were isolated from heparin- 
treated venous blood by means of density gradient cen- 
trifugation with Ficoll-Paque (Pharmacia LKB Biotech- 
nology AB, Uppsala, Sweden). Heparin-treated blood 
diluted 1:2 with Hanks balanced salt solution (HBSS) with 
0.35 gm/L sodium bicarbonate without phenol red or 
RPMI 1640 medium (Gibco, Grand Island, N.Y.) with 2 
mmol/L glutamine, 100 p~g/ml penicillin, and 100 /xg/ml 
streptomycin was layered on Ficoll-Paque and centrifuged 
at 800 g for 25 minutes. The PBMC were collected and 
washed twice in RPMI 1640. 
MC were isolated from lymph nodes or spleen by 
repeatedly flushing and aspirating a subeapsular portion 
of the tissues with 40 to 50 ml of RPMI 1640 through a 
23-gauge needle. The MC were dispersed by a further five 
aspirations through the needle and were then centrifuged 
over Ficoll-Paque at 800 g for 25 minutes and washed 
twice in RPMI 1640. MC and PBMC were then resus- 
pended in RPMI 1640 with 20% human A serum and 20% 
DMSO (Sigma Chemical Co., St. Louis, Mo.) and cryo- 
preserved in liquid nitrogen at -196 ° C. All MC popula- 
tions were found to be greater than 95% viable by means 
of trypan blue exclusion after thawing for use in assays. 
Flow cytometric crossmatch. Serial serum specimens 
from recipients were tested for donor-specific antibodies 
against T and B cells from the AVA donor and human 
leukocyte antigens (HLA) A-, B-, C-, and DR-disparate 
third party control subjects by flow cytometric crossmatch 
(FCCM) as previously described. 6 MC were washed twice 
in HBSS containing 10% fetal bovine serum (FBS) and 
then preincubated in HBSS with 10% FBS at 37 ° C for 20 
minutes to reduce nonspecifie antibody binding. Donor 
and control MC (2 to 5 × 105 in 25 /xl) were incubated 
with 20/xl aliquots of recipient , pooled negative control, 
or pooled positive control serum at room temperature and 
then washed twice in HBSS containing 2% FBS. Negative 
sera were from normal subjects with no history of preg- 
nancy, blood transfusion, or organ transplantation. Posi- 
tive sera were from sensitized recipients of failed renal 
allografts with high-titer anti-HLA antibodies. 
The cells were incubated in the dark for 20 minutes at 
room temperature with 30 /xL of an antibody mixture 
containing 0.5 /~1 fluoreseein isothi0cyanate-conjugated 
F(ab')2 rabbit anti-human IgG or IgM (DAKO, Glostrup, 
Denmark), 5 ~1 Phycoerythrin (PE)-conjngated anti- 
CD20 (DAKO), and 2 ~1 PE-c0njugated anti-Leu 4 
(CD3) diluted with 10/xl of unconjugated anti-Leu 4-pu- 
rified antibody (Becton Dickinson, San Jose, Calif.) and 
HBSS with 2% FBS. The MC were then washed in HBSS 
with 2% FBS and fixed by the addition i50/zl of fixative 
(1% formalin, 2.5% glucose, and 0.2% sodium azide). 
Antibodies to T or B cells were detected by using dual 
color immunofluorescence in a flow cytometer (Coulter 
Elite, Hileah, Fla.). The level of bound antibody was 
expressed as the channel number of mean peak fluores- 
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Table I. Serial levels of recipient antibodies 
Targets* Day O? Day 10 Day 30 Day 90 Day 365 
Donor  T 17 _+ 6 17 -+ 7 208 + 173 543 -+ 218 511 _+ 267 
Donor  B 56 + 36 55 -+ 37 466 + 272 937 -+ 339 758 +_ 306 
Contr. T 15 _ 6 15 -+ 5 59 _+ 30 208 +- 58 243 _+ 190 
Contr. B 42 + 24 38 _+ 20 203 _ 147 456 +- 254 431 _+ 228 
MV/XV T 24 + 1 24 _+ 2 25 _+ 1 24 _+ 3 nd 
MV/XV B 50 + 10 50 +- 7 52 _ 6 51 -+ 15 nd 
nd= Not done. 
*Serial aortic valve allograft (AVA) recipient sera were tested by flow cytometric crossmatch against T and B cells from AVA donors and HLA-disparate 
third-party controls. Mechanical or xenograft aortic valves (MV/XV) Were tested against control cells. Day 0 sera were collected immediately before AVA 
surgery. 
"~Values hown represent the mean -+ 1 standard eviation of peak channel fluorescence for each of the days. 
cence intensity on a 3-decade log scale. To ensure consis- 
tency between assays, aliquots of the pooled negative and 
positive control serum were used in each assay, and results 
were accepted only if the control results fell within 1 
standard deviation of the mean of repeated estimations. 
Reactivity toward T cells indicated the presence of anti- 
HLA class I antibodies, and B-cell reactivity indicated the 
presence of class I and/or class II antibodies. 6; 8 
Recipient antibody HLA specificity. Detection and 
specificity of recipient anti-HLA antibodies was deter- 
mined by typing against representative T- and B-cell 
panels using the National Institutes Of Health (NIH) 
microlymphocytotoxicity assay: 9 Undiluted sera in 1 /~1 
aliquots were added to Terasaki microwells prefilled with 
light mineral oil containing 2 /xl of T-cell or B-cell 
suspensions (at 2 × 106/L) previously isolated from pe- 
ripheral blood or spleen by immunomagnetic bead sepa- 
ration. After incubation for 30 minutes at room temper- 
ature, 5/xl of noncytotoxic rabbit complement was added 
for 90 minutes, and then 5 /xl of 4% aqueous eosin was 
admixed, followed in 2 minutes by 5 /xl of formalin to 
detect nonviable cells. Cytotoxicity was assessed manually 
in each microweii on a Lambda Scan Plus (One Lambda 
Inc., Los Angeles, Calif.) and graded on an increasing 
scale from 1 (<5% lysis) to 8 (>95% lysis). Antibody 
specificities were assigned by an experienced tissue-typing 
scientist in a blinded fashion according to the patterns of 
significant cytotoxicity. 
Mixed lymphocyte culture. All cryopreserved stimula- 
tor (donor) and responder (recipient) cells were thawed 
simultaneously for the mixed lymphocyte culture (MLC) 
assay. Recipient PBMC were used as responders to test 
for the presence of donor-specific proliferative T-cell 
responses against irradiated (2500 cGy) stimulator MC 
from donor and third-party control peripheral blood, 
spleen, or lymph nodes. Stimulator MC (1 × ! 0s) and 
responder PBMC (1 × 105) taken at each time before and 
after implantation were incubated for 2 days at 37 ° C in an 
atmosphere of 5% CO2 in air in quadruplicate in 200/xl of 
RPMI 1640 containing 20% human pooled sera, 2 mmol 
glutamine, 100/xg/ml penicillin, and 100/xg/ml streptomy- 
cin in round-bottom icrowells. 
Proliferation was measured on a beta scintillation 
counter (LKB Wallac 1205 Betaplate, Turku, Finland) 
after incubating the cells in each well with 1 /zCi of 
tritiated thymidine for 18 hours before harvesting. Triti- 
ated thymidine incorporation was expressed as the stim- 
ulation index (SI), calculated by the formula: SI = Mean 
counts per minute (experimental)/Mean counts per 
minute (autologous). Autologous counts were obtained by 
coculturing nonirradiated and irradiated responder MC at 
each time. 
Cell viability, as determined by means of trypan blue 
exclusion, was always greater than 95%, and proliferative 
ability of responders was confirmed in each assay by 
incubation with phytohemagglutinin (10/zg/well). 
Statistics. Comparisons between paired groups were 
made with the Wilcoxon matched-pair signed-rank test 
and beWveen unrelated pairs using the Wilcoxon rank sum 
test (Stata Statistical Package 3.0; Stata Corporation, 
College Station, Tex.). 
Results 
Recipient antibody response. Ten AVA recipients 
(numbers 1 through 10) studied serially by FCCM 
demonstrated antidonor IgG antibodies in every case 
(Table I and Fig. 1). Low levels of reactivity compara- 
ble to those of MV or XV recipients and pooled 
negative control sera (results not shown) were ob- 
served against donor T and B cells in all patients at 
days 0 and 10 after AVA implantation. 
Significantly increased reactivity was detected in 
recipients at 30 days (p < 0.005 for T cells and p < 
0.005 for B cells), 90 days (p < 0.005 andp < 0.005), 
and 365 days (p < 0.008 and p < 0.008) compared 
with day 0 antibody levels. There was no explanation 
for the markedly lower anti-T-cell and anti-B-cell 
antibody response observed in only one of the 
recipients (recipient 2), which by day 365 had fallen 
to within 3 standard deviations of the day 0 mean 
antibody levels. Significant IgM responses were not 
observed at any of the times for the first three 
patients tested (data not shown). The antibody 
levels of the four recipients who received only aortic 
valves did not differ significantly f rom those of the 
remaining six who received the larger combined 
valve and root replacements (data not shown). 
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Fig. 1. Anti-donor IgG antibodies measured serially by flow cytometric crossmatch. Mean antibody levels 
(with 1 standard eviation bars) are expressed as the channel number corresponding to peak cell 
fluorescence on a 3-decade log scale. The antibody levels against T (A) and B (B) cells are indicated for 
recipient sera tested against donor (D, I )  and third-party (O, 0) cells and for recipients of MV or XV 
tested against hird-party cells (©, ~). 
Recipient sera were also tested against T and B 
cells from normal control cells (selected to have no 
HLA A, B, and DR antigens in common with the 
AVA donor). All 10 recipients tudied showed 
significant reactivity to nondonor HLA antigens, but 
these responses were significantly lower than anti- 
donor responses at 30 days (p < 0.016 and p < 
0.028), 90 days (p < 0.003 andp < 0.003), and 365 
days (p < 0.038 and p < 0.012). Control recipients 
of MV or XV (including two recipients of blood 
transfusions) howed no significant increase in anti- 
body reactivity against control T and B cells (see 
Table 1 and Fig. 1). 
Recipient antibody HLA specificity. The HLA 
specificities of antibodies from 13 AVA recipients 
(recipients 1 through 13) at 90 days were identified 
by NIH microcytotoxicity (Table II). Donor HLA 
class I-  or class II-specific antibodies were demon- 
strated in 7 of 13 and 4 of 11 recipients, respectively. 
The anti-B27 antibody in patient 3 is a well-recog- 
nized cross reactivity with B7, and in patient 10, 
anti-B55 was strongly cross-reactive with B56, which 
was present in the donor, m' 11 Multispecific reactiv- 
ity against more than 50% of panel T and B cells was 
detected in all recipients. 
Broad reactivity against he screening cell panels 
is common in recipients after solid organ transplan- 
tation and may be mediated by antibodies directed 
Table II. HLA specificities of recipient antibodies 
Class I Class H 
1 ~,  B35, B51* - -  
2 ~2 I 
3 ~4,  B55, B7, B27 DQ1 
4 I I 
5 I I 
6 - -  DR l l  
7 - -  DR7 
8 B7 DQ1 
9 I I 
10 ~4,  B55 , B57 - -  
11 A2 nd 
12 A2 nd 
13 - -  - -  
- - ,  no specific antibodies detected; nd, Not done. 
*The data in bold type indicate antigens in the aortic valve allograft donor. 
Numbers represent individual recipients. 
against monomorphic HLA determinants or non- 
HLA surface antigens. All four recipients lacking 
donor-specific antibodies had greater than 90% 
multispecific panel reactivity, which might have ob- 
scured specific HLA reactivities. In AVA recipients 
antibodies specific for donor HLA that target Class I
developed more frequently than class I! antigens. 
Recipient T-cell responses. Peripheral blood T 
cells taken from seven recipients (recipients 10 and 
15 through 20) before and after AVA implantation 
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Table III. Recipient mixed lymphocyte culture reactivity against donor and control peripheral blood mixed 
lymphocytes 
Patients Day 0 Day 10 Day 30 Day 90 
10-D* 4.4 2.2 9.0 7.5 
10-C 2.3 1.6 2.7 2.6 
15-D 1.9 1.7 7.3 3.9 
15-C 2.9 1.6 2,8 3.9 
16-D 2.2 4.1 66.7 13.7 
16-C 3.5 6.6 13.1 10.9 
17-D 4.7 6.3 33.8 30.9 
17-C 5.4 7.5 12.3 14.2 
18-D 7.6 - -  22.6 13.6 
18-C 5.5 - -  13.0 6.9 
19-D 8.0 6.8 8.6 15.0 
19-C 3.7 4.0 4.5 6.2 
20-D 3.0 3.5 8.6 15.0 
20-C 6.3 6.6 8.2 8.4 
Donor 4.5 -+ 2.5 4.1 ± 2.1 22.4 _+ 22.0 12.7 _+ 9.2 
Control 3.9 _+ 1.3 4.7 + 2.6 8.1 +_ 4.8 7.6 -+ 4.0 
Values shown for each subject (indicated by number) are the stimulation i dices from the mixed lymphocyte culture against donor (D) and control (C). Values 
in the last two rows represent mean + 1 standard eviation of stimulation i dices. Control stimulator cells were from HLA-disparate third parties. 
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Fig. 2. Recipient T-cell reactivity measured serially in a 
one-way mixed lymphocyte culture. Reactivities (ex- 
pressed as mean stimulation indices with 1 standard 
deviation bars) against donor (E3) and third-party cells (O) 
are shown. 
were investigated for proliferative responses against 
stimulator donor PBMC in a one-way 2-day MLC 
(Fig. 2 and Table III). The objective of these 
experiments was to detect an accelerated T-cell 
response to donor PBMC in recipients by comparing 
the MLC reactivities of each individual at certain 
times after surgery with baseline levels before im- 
plantation. Significantly increased recipient reactiv- 
ity toward donor PBMC was observed in samples 
taken at 30 days in recipients (p < 0.018) compared 
with the day 0 preimplantation mean SI; mean levels 
at 10 days and 90 days were not significantly differ- 
ent (p < 0.917 andp < 0.18, respectively). 
The specificity of the anti-donor T-cell response 
was investigated by the inclusion of HLA-dispar- 
ate control stimulator PBMC in the MLC at each 
time point for the seven recipients. There was no 
significant difference between donor and third- 
party reactivity at any of the times, although there 
was an evident rend at 30 days (p < 0.142 at 30 
days). The MLC reactivity to donor or third-party 
cells was not atypical in two of the recipients who 
received blood transfusions, both of whom had 
levels of reactivity toward the lower end of the 
range. Patient 18 (who had received an AVA 6 
years previously) had the third highest levels of 
donor-specific MLC reactivity. These data indi- 
cate that 30 days after AVA implantation irecipi- 
ents have significantly increased numbers of cir- 
culating alloreactive T cells compared with their 
preimplantation baseline. 
Discuss ion 
Previously there were limited data available on 
the immunogenicity of the human cryopreserved 
AVA, but this study shows that all recipients are 
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likely to form IgG- and T-cell-mediated reactions to 
donor HLA antigens. Developing in parallel with 
this specific reactivity were broadly reactive antibod- 
ies, which occur in recipients of vascularized solid 
organ allografts. 9-11 The wide range of T-cell reac- 
tivities may reflect the degree of HLA mismatch 
between recipient and donor. Long-term clinical 
studies would be required to determine whether the 
degree of T-cell stimulation could be one determi- 
nant of accelerated AVA degeneration. 
T cells of the CD4 ÷ "helper" phenotype initiate 
MLC reactivity by recognition of nonself HLA class 
II molecules and associated costimulatory B7 mole- 
cules on donor antigen-presenting cells. The T-cell 
and antibody responses observed in AVA recipients 
probably are supported by the cytokine-secreting 
functions of this T-cell subset. 12' 13 
Donor-specific T cells are likely to be the main 
agents of AVA injury, effected through secretion of 
high levels of cytokines such as interleukin-2 and 
interferon-7, which have proinflammatory and cy- 
todestructive potential. 13-15 Anti-donor antibodies 
accompanying AVA implantation are likely to be a 
relatively innocuous consequence of T-cell activa- 
tion. Anti-HLA antibodies frequently arise after 
solid organ allograft implantation without adverse 
impact on graft function, in contrast to the preexist- 
ing antibodies that predispose to hyperacute rejec- 
tion. 16 
Past experimental and clinical studies have 
proved that aortic vane tissue is immunogenic. 
Anti-donor antibody responses followed implanta- 
tion of fresh AVA in a rat model 6 and in human 
recipients of noncryopreserved AVA in whom anti- 
HLA antibodies were detected as early as 1 week. In 
this clinical study, only donor HLA class I-specific 
antibodies were identified, perhaps because of re- 
duced or altered viability of the AVA. 17 Recipient 
proliferative or cytotoxic T-cell responses to fresh or 
cryopreserved AVA were detected in vivo in animal 
models.6, 18-20 In vitro fresh or cryopreserved human 
aortic valve fragments or valve-derived endothelial 
cells stimulated allogeneic T cells, m 
The location of induction and amplification of the 
immune response to the AVA remains unknown. 
Dendritic ells, which have been identified in human 
great vessels, 22 together with endothelial cells, are 
capable of presenting foreign HLA class I and II 
antigens to recipient T cells. 2~' 23, 24 After an immu- 
nologic reaction involves the AVA, the density of 
HLA antigens on these cells and surviving fibro- 
blasts and myocytes would be amplified by locally 
secreted interferon-,/ and tumor necrosis factor- 
OL.14, 15 Approximately 50% of AVA fibroblasts ur- 
vive cryopreservation, 3' 7 but the extent to which 
endothelial and dendritic cells retain function is 
unknown. If alloantigen-presenting cells survive in 
the AVA, initial activation of T cells may occur in 
the graft, but presentation of donor HLA antigens 
liberated from the AVA may also occur in regional 
lymph nodes. Periodic reactivation of primed T cells 
by recirculation through the graft or nodes would 
maintain the allogeneic response until all HLA 
antigen in the valve was degraded. 
What are the consequences of a humoral and 
cellular allogeneic response arising against a cryo- 
preserved AVA? There are few clinical data from 
which to gauge the pathogenic potential of the 
human AVA response. Although the limited num- 
bers of explanted AVA do not reveal convincing 
signs of an immunologic reaction, the occurrence of 
leaflet thickening, fibrosis, and calcification in the 
young recipient strongly suggests immunologic valve 
damage.4, 5 
Implantation of a cryopreserved AVA stimulates 
a substantial immune response to donor antigens 
that may destroy viable matrix fibroblasts. In the 
absence of repair and remodeling functions pro- 
vided by fibroblasts, accelerated deterioration of the 
matrix may lead to degenerative failure. A limited 
course of immune suppression designed to minimize 
the immune response to AVA antigens may en- 
hance the long-term survival of matrix fibroblasts. 
However, the risks of immune suppression would 
have to be very low because of the current clinical 
performance of the AVA (70% freedom from struc- 
tural deterioration at 20 years). 25 Further studies will 
explore the potential benefit of immune suppression i
animal AVA models and will identify the cytokines 
involved in the human response to the AVA. 
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Discussion 
Dr. Mark F. Lupinetti (Seattle, Wash.). I congratulate 
Dr. Hogan and his associates for their outstanding contribu- 
tion to our understanding of the consequences of allograft 
valve implantation. These data unequivocally demonstrate 
that the recipient of an allograft valve is sensitized to the 
donor antigens and that this sensitization persists for a long, 
long time. This is an elegant extension of your laboratory's 
experimental studies. It is of great reassurance to those of us 
who have relied heavily on the rat allograft valve model 
because it suggests that extrapolations made from that 
model do have validity to humans. 
[ think these findings are very important clinically 
because they demonstrate the limited ability of cryo- 
preservation processing in altering immunogenicity. I 
think these findings are also important clinically because 
the durability of the sensitization suggests that a short 
course of immunosuppression, as someone suggested, is
unlikely to be efficacious. 
[ would like to ask for your comments, Dr. Hogan, 
regarding two areas of further inquiry that are suggested by 
your research. First, what, if any, evidence is there that the 
sensitization reproducibly contributes to degeneration f the 
valve? I infer from your manuscript that the patients in this 
study are continuing to do well and the valves are continuing 
to function. It seems, then, that we are left with a tissue that 
is uniformly immunogenic but one that your institution has 
shown can be expected to last for 15 years, 20 years, and 
maybe longer. How do we make sense of this? 
Second, are our current methods of immunologic assay 
sufficiently precise to allow us to grade sensitization? Can 
we identify patients as being strongly sensitized or weakly 
sensitized to predict which patients may be at greater or 
lesser risk for valve-related complications? If that is true, 
should we be performing routine immune surveillance on 
all recipients of allograft valves? 
Dr. Hogan. Thank you for your comments. Your first 
question is the crux of the matter, which given the 
constraints on the human system, is unanswerable. At a 
previous session I asked whether there might be very 
sensitive echocardiographic methods that could detect 
thickening and nodularity of the valve. Detailed imag- 
ing studies may give some idea of what is happening 
early on in the implanted valve. I doubt whether there 
is ever going to be an answer to this question, and if we 
do eventually come to immune suppression, the clinical 
end points are years out. I really cannot answer the first 
question better than that. I guess that is why we are 
looking at cytokines. Maybe we will see some critical 
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early difference in cytokines between controls and 
allografts. 
I have already alluded to the second question. I think 
that the immunologic parameters to observe are the T 
cells, which we can look at and detect in a shortened 
MLC. If anything destroys the valves, it will be T cells. 
Perhaps those three individuals with the high T-cell 
reactivities out of proportion to the others may be the 
ones that we have to watch. 
I agree entirely with you regarding immune suppres- 
sion. We could use a drug such as cyclosporine for the first 
2 to 3 months after implantation, stop the drug, and then 
see an immune response. Alternatively, immune suppres- 
sion for the first several months may protect the valve 
until alterations uch as loss of endothelium ake the 
valve an immunologically privileged site. The valve would 
be less prone to attack at that stage, and remaining viable 
fibroblasts would be protected. 
Dr. David B. Ross (Halifax, Nova Scotia, Canada). We 
found in a small series of children with homografts in 
the right ventricular outflow tract that very short pres- 
ervation times similar to those you reported were 
associated with increased failure. Have you looked at 
whether children have a qualitatively or a quantitatively 
different response than this group of adults that you 
have presented? 
Do you have any information about which of these 
adults, if any, received blood transfusions? Is it possible 
that children do more poorly because ahigher percentage 
of them would have received multiple transfusions atthis 
operation or during previous ones? 
Dr. Hogan. No, we haven't looked at children, and that 
study needs to be done. I would be surprised if the results 
were qualitatively different from what we have shown. 
There are a few things that I omitted from the data, and 
one was that there was no relation between results and 
parameters such as blood transfusions and whether the 
patients got a large amount of tissue in an aortic root or 
just got a subcoronary valve. There was no relation to 
blood transfusions. 
Dr. Alain F. Carpentier (Paris, France). Have you 
analyzed separately the aortic remnants and the valve cusp 
for anti-T and anti-B antibodies, and if so, was there any 
difference? If there is a difference, knowing that calcifica- 
tion is more common in the aortic remnant, do you see 
any correlation between calcification and immunologic 
reaction, and have you analyzed the calcium content on 
these two parts? Was there any correlation between valve 
failure and recipient T-cell reactivity? 
Dr. Hogan. The studies that I described were done in 
the last 24 months, and we do not have any clinical 
correlates for the cohort of 20 patients. I cannot ell you 
whether there is a correlation between these immunologic 
findings and calcification or valve failure. In an abstract 
presented at another meeting earlier this year, donor- 
reactive recipient T cells were cultured from explanted 
valves. Whether the T cells were damaging the valve is 
unknown. 
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